SAN FRANCISCO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- CarMax, Inc. (NYSE: KMX) shareholders endured a sharp sell-off on September 25, 2025, with the stock plummeting nearly 20% following the release of its second-quarter 2026 financial results. The catalyst for the decline was a surprise surge in the provision for loan losses within the company’s CarMax Auto Finance (CAF) segment, its in-house financing arm. This development and severe market reaction has prompted national shareholders rights firm Hagens Berman ...

Core Insights - aTyr Pharma, Inc. experienced a significant drop in share price, over 80%, following the announcement that its late-stage study of efzofitimod for pulmonary sarcoidosis did not meet its primary endpoint [1][5] Company Developments - The company reported that the topline results of the EFZO-FIT trial failed to achieve statistical significance in steroid reduction after a year of forced tapering, with placebo tapering outperforming the company's projections [5] - aTyr had previously assured investors that its Phase 2 data was among the best seen by experts and emphasized a multi-billion-dollar market opportunity for efzofitimod [4] Market Reaction - Following the disappointing trial results, the market reacted sharply, leading to a significant decline in aTyr's share price and prompting numerous analyst downgrades [5] Legal Investigation - Hagens Berman, a national shareholders rights firm, has initiated an investigation into whether aTyr misled investors regarding the Phase 2 data and the design of the Phase 3 EFZO-FIT trial [2][6] - The firm is encouraging investors who suffered losses to come forward and is seeking information from individuals who may assist in the investigation [2][6]

Core Insights - aTyr Pharma, Inc. experienced a dramatic decline in share price, dropping over 80% after failing to meet the primary endpoint in its late-stage study of efzofitimod for pulmonary sarcoidosis [1][5] Company Performance - The topline results from the EFZO-FIT trial indicated that the primary goal of steroid reduction was not achieved, with placebo tapering outperforming the company's expectations [5] - aTyr previously claimed that its Phase 2 data was among the best seen by experts and highlighted a multi-billion-dollar market opportunity for efzofitimod [4] Market Reaction - Following the disappointing trial results, the market reacted severely, leading to a significant drop in share price and numerous analyst downgrades [5] Legal Investigation - Hagens Berman, a national shareholders rights firm, has initiated an investigation into aTyr for potentially misleading investors regarding the Phase 2 data and the design of the Phase 3 trial [2][6] - The investigation is focused on the accuracy of aTyr's disclosures and the implications of the failed trial results on investor expectations [3][6]

Company Overview - aTyr Pharma, Inc. experienced a significant decline in share price, dropping over 80% following the announcement that its late-stage study of efzofitimod for pulmonary sarcoidosis did not meet its primary endpoint [1][5]. Market Reaction - The market reacted severely to the topline results call on September 15, 2025, where aTyr reported that the trial failed to achieve statistical significance in steroid reduction, with placebo tapering outperforming the company's expectations [5]. Investigation Details - Hagens Berman, a national shareholders rights firm, has initiated an investigation into aTyr for potentially misleading investors regarding the Phase 2 data and the design of the Phase 3 EFZO-FIT™ trial [2][6]. - The investigation is focused on the accuracy of aTyr's disclosures about the quality of its Phase 2 efzofitimod data and the trial design [3][6]. Company Claims - aTyr previously assured investors that its Phase 2 data was among the best seen by experts and claimed that efzofitimod could dominate the ILD market, which was described as a multi-billion-dollar opportunity [4][6].

Core Viewpoint - America's Car-Mart, Inc. experienced a significant decline in share price following the release of its Q1 2026 financial results, which were adversely affected by tariff impacts and other operational challenges [1][6]. Financial Performance - For Q1 2026, Car-Mart reported a sales volume decline of 5.7%, with units sold decreasing from 14,391 to 13,568 compared to the previous year [6]. - The company's share price fell by over 18%, dropping $8.14 on September 4, 2025, following the financial results announcement [1][6]. Investor Concerns - Hagens Berman, a national shareholders rights firm, has initiated an investigation into whether Car-Mart misled investors regarding its receivables and customer risks, particularly in relation to tariff impacts [2][3]. - The investigation is focused on the accuracy of Car-Mart's disclosures about the risks posed by tariffs, especially after the company previously assured investors of manageable impacts [4][7]. Disclosure Issues - In mid-June 2025, Car-Mart claimed to have effectively managed tariff impacts, stating an increase of only $300 per vehicle unit [4]. - However, subsequent disclosures revealed the need to enhance transparency regarding loan modifications for financially distressed borrowers, leading to a stock price drop of $3.12 (5.2%) on July 15, 2025, and a further decline of $3.70 (7.5%) on July 30, 2025, when the company stated that prior financial statements should no longer be relied upon [5][6]. Legal and Regulatory Actions - The investigation by Hagens Berman is seeking information from investors who may have suffered losses and from individuals with knowledge that could assist in the inquiry [2][7]. - Whistleblowers with non-public information regarding Car-Mart are encouraged to come forward, with potential rewards for information leading to successful recovery by the SEC [7].

SAN FRANCISCO, July 21, 2025 (GLOBE NEWSWIRE) -- On May 6, 2025 investors in BellRing Brands, Inc. (NYSE: BRBR) saw the price of their shares decline about 19% after BellRing announced during its Q2 2025 earnings call that it anticipated Q3 2025 reduction in retailer inventory levels. This announcement has prompted national shareholders rights firm Hagens Berman to open an investigation into whether BellRing Brands may have violated the securities laws concerning the company’s sales practices. The firm urge ...